Skip to content

Exogenous Sodium Lactate Infusion in Traumatic Brain Injury (ELI-TBI)

Exogenous Sodium Lactate Infusion in Traumatic Brain Injury (ELI-TBI)

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02776488
Acronym
ELI-TBI
Enrollment
0
Registered
2016-05-18
Start date
2020-09-30
Completion date
2026-06-30
Last updated
2021-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Traumatic

Keywords

brain trauma, metabolic therapy

Brief summary

Metabolic crisis is a state of energy insufficiency due to impaired mitochondrial function as indicated by cerebral microdialysis lactate/pyruvate ratio (LPR). We have performed preliminary mechanistic analysis of alternative fuels in humans and have demonstrated proof of concept that exogenous fuels alter brain metabolism. We will conduct a multicenter, adaptive design-based, proof of concept phase 2 safety study of candidate supplemental fuels in patients with severe traumatic brain injury to determine safety and efficacy.

Detailed description

Metabolic crisis is a state of energy insufficiency due to impaired mitochondrial function as indicated by cerebral microdialysis lactate/pyruvate ratio (LPR). We have performed safety analysis of exogenous sodium lactate infusions in humans and have demonstrated proof of concept that these fuels alter brain metabolism. Animal TBI studies have demonstrated proof of concept for exogenous lactate and pyruvate. We will conduct a multicenter, adaptive design-based, proof of concept biomarker mechanistic safety study of exogenous sodium lactate. The preliminary goal is to determine if exogenous lactate infusion is safe and has a demonstrated effect on selected biomarkers.

Interventions

Infusion of exogenous sodium lactate

DRUGPlacebo

Infusion of normal saline

Sponsors

University of California, Los Angeles
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Intervention model description

Dose ranging and then RCT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients seen in the Medical Center Emergency Department * Adult patients transferred to the Neurocritical Intensive Care Unit with a physician's diagnosis of brain injury. * GCS 3-12

Exclusion criteria

* Pregnancy at time of injury * History of diabetes mellitus * History of hemodynamic instability * Known terminal illness which alters brain functioning * Diagnosed AIDS progressed to AIDS dementia * Known history of chronic severe neurological disturbance * Severe retardation * Previous severe diminished mental capacity * No command of either English or Spanish * Arrest for a felony * Active neurologic condition such as stroke, recent TBI * metabolic disorder * preexisting hyperlactatemia * instability precluding experimental intervention

Design outcomes

Primary

MeasureTime frameDescription
Mortality within 30 days30 daysPercentage mortality within 30 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026